Laboratory Corporation of Ameri found using ticker (LH) have now 14 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 380 and 215 calculating the mean target price we have 340.57. With the stocks previous close at 276.75 this would imply there is a potential upside of 23.1%. There is a 50 day moving average of 271.42 and the 200 moving average now moves to 284.23. The market cap for the company is $25,743m. Find out more information at: https://www.labcorp.com
The potential market cap would be $31,680m based on the market concensus.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women’s health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company has a collaboration agreement with community clinical oncology research network, LLC to understand the impact of disparities in precision medicine for people with cancer; and strategic collaboration with GeneCentric Therapeutics It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
